ISRCTN48489393
Completed
Not Applicable
Heart protection study
Medical Research Council (MRC) (UK)0 sites20,000 target enrollmentApril 6, 2000
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Coronary heart disease (CHD)
- Sponsor
- Medical Research Council (MRC) (UK)
- Enrollment
- 20000
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients at high risk of CHD (e.g., because of history of vascular disease or diabetes)
- •2\. Without clear indication for or contra\-indication to statin
- •3\. Male and female adults
- •4\. Non\-fasting blood total cholesterol concentrations of at least 3\.5 mmol/L (135 mg/dL)
Exclusion Criteria
- •1\. The patient's doctor considered statin therapy to be clearly indicated or contra\-indicated
- •2\. A past history of: stroke, myocardial infarction or angina hospitalisation within the previous six months
- •3\. Chronic liver disease or evidence of abnormal liver function
- •4\. Severe renal disease or evidence of substantially impaired renal function
- •5\. Inflammatory muscle disease or evidence of muscle problems
- •6\. Concurrent treatment with cyclosporin, fibrates or high\-dose niacin
- •7\. Child\-bearing potential
- •8\. Severe heart failure
- •9\. Life\-threatening conditions other than vascular disease or diabetes (including any cancer except non\-melanoma skin cancer)
- •10\. Any other condition that might limit long\-term compliance
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Remote ischaemic postconditioning in the clinical settingTopic: Cardiovascular, NeurologicalSubtopic: Cardiovascular (all Subtopics), Neurological (all Subtopics)Disease: Cardiovascular, Nervous system disordersCirculatory SystemMyocardial ischaemia-reperfusion injuryISRCTN78348355niversity College London (UCL) (UK)500
Recruiting
Not Applicable
Study on providing cardiovascular disease prevention services using telemonitoring with IoT medical devicesHeart failureJPRN-UMIN000051144General Incorporated Association telemedEASE10
Active, not recruiting
Phase 1
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesEUCTR2015-003563-10-ROovo Nordisk A/S3,183
Active, not recruiting
Phase 1
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesEUCTR2015-003563-10-ITOVO NORDISK. S.P.A.3,183
Active, not recruiting
Phase 1
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesEUCTR2015-003563-10-GBovo Nordisk A/S3,183